Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era-Reference-Cited by-同舟云学术

Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era

Published:2015-01-14 Issue:7 Volume:56 Page:2047-2055
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Lu Chieh-Sheng,Chen Jia-Hong,Huang Tzu-Chuan,Wu Yi-Ying,Chang Ping-Ying,Dai Ming-Shen,Chen Yeu-Chin,Ho Ching-Liang

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.982636

Reference48 articles.

1. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

3. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

4. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone

5. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of clinical characteristics and baseline 18F-FDG PET/CT quantization parameters in primary adrenal diffuse large B-cell lymphoma: a preliminary study;Quantitative Imaging in Medicine and Surgery;2023-12

2. An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas;Cancer Discovery;2022-10-20

3. Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis;Aging and Cancer;2022-09

4. Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era;Clinica Chimica Acta;2022-07

5. Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis;Hematology;2022-06-26